Jinfiniti Precision Medicine

Jinfiniti built a durable niche by solving a real measurement problem before selling the fix: it operates a high-complexity CLIA lab and developed what it describes as the first clinical-grade intracellular NAD+ test in 2019, and it claims to process the large majority of NAD+ tests performed worldwide — a genuine reference-standard position in a biomarker that has become central to the longevity conversation. The model is elegantly self-reinforcing: customers do a finger-prick blood-spot test at home, receive a personalized NAD+ report with dosage guidance, buy Jinfiniti's Accuri Vitality Boost (an NMN formulation combined with creatine monohydrate, D-ribose, and niacinamide that the company says optimizes NAD+ in roughly 85% of users), then retest to confirm improvement — a test-supplement-retest loop that drives recurring revenue and hard data most supplement sellers cannot offer. That measurement layer is the moat: in a NAD+ market flooded with unvalidated liposomal products of wildly variable potency, Jinfiniti can point to intracellular test results showing its formulation outperforming competitors, turning objective diagnostics into a marketing weapon. Founded in 2018 by Georgia Research Alliance Eminent Scholar Dr. Jin-Xiong She, the company pairs scientific credibility with a clinician and practitioner channel, and it has extended the same test-and-optimize logic to oxidative stress and senescent-cell burden — a platform for actionable aging biomarkers rather than a one-product supplement brand.